Cargando…
Hematologic toxicities of chemotherapy in breast and ovarian cancer patients carrying BRCA1/BRCA2 germline pathogenic variants. A single center experience and review of the literature
BRCA1 and BRCA2 play a central role in DNA repair and their germline pathogenic variants (gBRCA) confer a high risk for developing breast and ovarian cancer. Standard chemotherapy regimens for these cancers include DNA-damaging agents. We hypothesized that gBRCA carriers might be at higher risk of d...
Autores principales: | Hu-Heimgartner, Ketty, Lang, Noémie, Ayme, Aurélie, Ming, Chang, Combes, Jean‑Damien, Chappuis, Victor N., Vazquez, Carla, Friedlaender, Alex, Vuilleumier, Aurélie, Bodmer, Alexandre, Viassolo, Valeria, Sandoval, José L, Chappuis, Pierre O., Labidi-Galy, S. Intidhar |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Netherlands
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10276105/ https://www.ncbi.nlm.nih.gov/pubmed/37119509 http://dx.doi.org/10.1007/s10689-023-00331-6 |
Ejemplares similares
-
Clinical outcome of breast cancer in carriers of BRCA1 and BRCA2 mutations according to molecular subtypes
por: Talhouet, Solene De, et al.
Publicado: (2020) -
Publisher Correction: Clinical outcome of breast cancer in carriers of BRCA1 and BRCA2 mutations according to molecular subtypes
por: De Talhouet, Solene, et al.
Publicado: (2020) -
Evidence for accelerated aging in mammary epithelia of women carrying germline BRCA1 or BRCA2 mutations
por: Shalabi, Sundus F., et al.
Publicado: (2021) -
A new bioinformatics tool to help assess the significance of BRCA1 variants
por: Cusin, Isabelle, et al.
Publicado: (2018) -
Opportunities for improving triple‐negative breast cancer outcomes: results of a population‐based study
por: Rapiti, Elisabetta, et al.
Publicado: (2017)